Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer

James W. Antoon, William D. Meacham, Melyssa R. Bratton, Evelyn M. Slaughter, Lyndsay V. Rhodes, Hasina Ashe, Thomas Wiese, Matthew E. Burow, Barbara S. Beckman

Journal of Molecular Endocrinology · 2011 · 49 citations · 41 references

DOIFull text

Open access

Concepts

Abstract

Recently, crosstalk between sphingolipid signaling pathways and steroid hormones has been illuminated as a possible therapeutic target. Sphingosine kinase (SK), the key enzyme metabolizing pro-apoptotic ceramide to pro-survival sphingosine-1-phosphate (S1P), is a promising therapeutic target for solid tumor cancers. In this study, we examined the ability of pharmacological inhibition of S1P formation to block estrogen signaling as a targeted breast cancer therapy. We found that the Sphk1/2 selective inhibitor (SK inhibitor (SKI))-II, blocked breast cancer viability, clonogenic survival and proliferation. Furthermore, SKI-II dose-dependently decreased estrogen-stimulated estrogen response element transcriptional activity and diminished mRNA levels of the estrogen receptor (ER)-regulated genes progesterone receptor and steroid derived factor-1. This inhibitor binds the ER directly in the antagonist ligand-binding domain. Taken together, our results suggest that SKIs have the ability to act as novel ER signaling inhibitors in breast carcinoma.

References

41